Eli Lilly EPS Forecasts Rise 4.4% to $33.80 with Q1 Revenue Up 38.9%
Shares fell 5.9% over the past month versus a 0.8% S&P decline and a 3.1% industry gain. Consensus EPS forecasts for this fiscal year climbed 4.4% to $33.80 and Q1 revenue is projected at $17.68 billion (+38.9%).
1. Recent Stock Performance
Eli Lilly shares have returned -5.9% over the past month, underperforming the S&P 500 composite’s -0.8% change and lagging the Zacks Large Cap Pharmaceuticals industry’s +3.1% gain during the same period.
2. Earnings and Revenue Forecast Revisions
Analysts now expect Lilly to report $7.37 in EPS for the current quarter, down 2.4% over the past 30 days, while full-year EPS estimates rose 4.4% to $33.80. Revenue projections hit $17.68 billion for Q1 (+38.9%), $81.64 billion for the current fiscal year (+25.3%) and $93.53 billion next year (+14.6%).
3. Last Reported Results and Valuation
In its last quarter, Lilly posted $19.29 billion in revenue (+42.6%) and $7.54 EPS versus $5.32 a year ago, delivering revenue and EPS surprises of +7.95% and +7.87%. The stock carries a Zacks Rank #3 (Hold) and a Value Style Score of C, indicating it trades roughly in line with peers.